Impact of SLCO4C1 Genotypes, Creatinine, and Spironolactone on Digoxin Population Pharmacokinetic Variables in Patients With Cardiac Insufficiency

Clin Ther. 2021 Apr;43(4):788. doi: 10.1016/j.clinthera.2021.02.005. Epub 2021 Mar 18.

Authors

Pengqiang Du¹, Aifeng Wang¹, Yongcheng Ma¹, Ao Jia¹, Yafei Li¹, Xingang Li²

Affiliations

¹ Department of Pharmacy, Fuwai Central China Cardiovascular Hospital, Central China Fuwai Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
² Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Electronic address: lxg198320022003@163.com.

PMID: 33744001
DOI: 10.1016/j.clinthera.2021.02.005

No abstract available

Publication types

Letter
Comment

MeSH terms

Creatinine
Digoxin
Genotype
Heart Failure* / drug therapy
Heart Failure* / genetics
Humans
Organic Anion Transporters*
Spironolactone

Substances

Organic Anion Transporters
SLCO4C1 protein, human
Spironolactone
Digoxin
Creatinine